Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: aminolevulinic acid Clear all
Terminated Phase 2 Interventional

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

NCT02728388
View directory record Official record
Conditions
NEUROFIBROMATOSIS 1
Interventions
aminolevulinic acid
Drug
Lead sponsor
Donald Basel
Other
Eligibility
14 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Withdrawn Phase 2 Interventional

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

NCT01445691
View directory record Official record
Conditions
Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Intracranial Neoplasms, Neoplasms, Brain, Neoplasms, Intracranial, Primary Brain Neoplasms, Primary Malignant Brain Neoplasms, Primary Malignant Brain Tumors, Gliomas, Glioblastoma
Interventions
5-ALA (Gliolan)
Drug
Lead sponsor
Constantinos Hadjipanayis
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 9, 2026, 4:02 AM EDT
Active, not recruiting Phase 1 Interventional

Photodynamic Therapy For Onychomycosis

NCT07756671
View directory record Official record
Conditions
Onychomycosis of Toenail
Interventions
ALA 10% gel, PDT, Urea
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Arlington, Texas • Houston, Texas • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

NCT05080764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Not applicable Interventional Results available

The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy

NCT02594644
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Microneedle Roller, Aminolevulinic Acid, Blue Light
Device · Drug · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses

NCT03327831
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aminolevulinic Acid
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Not applicable Interventional

Photodynamic Therapy for Prevention of Nonmelanoma Skin Cancer in Organ Transplant Recipients

NCT02751151
View directory record Official record
Conditions
Nonmelanoma Skin Cancers
Interventions
have Levulan Kerastick (aminolevulinic acid) solution
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Oral Premalignant Lesions With 5-ALA PDT

NCT00571974
View directory record Official record
Conditions
Leukoplakia, Erythroplakia
Interventions
PDL-585, ScleroPLUS laser, 5-Aminolevulinic Acid (Levulan KerastickTM), Fluorescence Diagnosis Imaging
Device · Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Not applicable Interventional Results available

Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses

NCT01053000
View directory record Official record
Conditions
ACTINIC KERATOSES
Interventions
Tazorac
Drug
Lead sponsor
Stewart, Roger H., M.D., P.A.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Early Phase 1 Interventional

Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis

NCT03114111
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
aminolevulinic acid (ALA), Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 9, 2026, 4:02 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

NCT01475955
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Broad Area ALA 1-hour incubation, Broad Area ALA 2 hour incubation, broad area ALA 3-hour incubation, Spot ALA 2 hour incubation, Vehicle PDT, Blue Light Treatment
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses

NCT06027619
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Topical aminolevulinate (10% ALA gel), Red light illumination
Drug · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 9, 2026, 4:02 AM EDT
Withdrawn Phase 1 Interventional

A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer

NCT01611584
View directory record Official record
Conditions
Lung Cancer in Normal and Malignant Tumors
Interventions
ALA-induced Fluorescence
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 9, 2026, 4:02 AM EDT
Withdrawn No phase listed Observational

Use of 5-Aminolevulinic Acid to Assess Bone and Tissue Profusion in Orthopaedic Infection Patients

NCT04976049
View directory record Official record
Conditions
Trauma, Infection, Bone Fracture
Interventions
Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery
Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Not applicable Interventional Results available

Near Infrared Fluorescence Imaging for Bladder Cancer Detection

NCT03058705
View directory record Official record
Conditions
Bladder Cancer
Interventions
Hexaminolevulinate HCL, Near Infrared Fluorescence (NIRF)
Drug · Device
Lead sponsor
Edward Messing
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 1 Interventional

Fluorescence Guided Resection of Brain Tumors

NCT00870779
View directory record Official record
Conditions
Brain Tumors
Interventions
5-aminolevulinic acid
Drug
Lead sponsor
David W. Roberts
Other
Eligibility
21 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage

NCT07053852
View directory record Official record
Conditions
Actinic Keratoses, Photodamage
Interventions
Ameluz, Sciton HEROic
Drug · Device
Lead sponsor
Sherrif Ibrahim
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Victor, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Terminated Phase 4 Interventional Results available

Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

NCT01203878
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Photodynamic therapy, Imiquimod
Drug
Lead sponsor
Tennessee Clinical Research Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Englewood, Colorado • Charlotte, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Oct 9, 2026, 4:02 AM EDT
Not yet recruiting Phase 2 Interventional

A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients

NCT06907485
View directory record Official record
Conditions
Pediatric Brain Tumor
Interventions
Aminolevulinic acid hydrochloride
Drug
Lead sponsor
Costas Hadjipanayis
Other
Eligibility
2 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional

Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma

NCT00752323
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aminolevulinic acid, Surgical Resection
Drug · Procedure
Lead sponsor
Andrew Sloan, MD
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Early Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides

NCT03281811
View directory record Official record
Conditions
Refractory Mycosis Fungoides
Interventions
Aminolevulinic Acid Hydrochloride, Photodynamic Therapy, Quality-of-Life Assessment, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 9, 2026, 4:02 AM EDT
Not listed Not applicable Interventional

5-ALA in Recurrent Glioma

NCT02119338
View directory record Official record
Conditions
Glioma
Interventions
5-ala
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 9, 2026, 4:02 AM EDT
Recruiting Phase 2 Interventional

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

NCT07225621
View directory record Official record
Conditions
Glioblastoma, GBM
Interventions
5-ALA HCl + LIDU SDT, Placebo + Sham SDT
Combination Product
Lead sponsor
Alpheus Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Boston, Massachusetts • Rochester, Minnesota • Albany, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 9, 2026, 4:02 AM EDT